The portable, easy-to-use BD Veritor™ Plus System for Rapid Detection of RSV provides reliable results in 10 minutes.
When your pediatric patients† need fast, reliable RSV testing, turn to the BD Veritor™ Plus System. Offering reliable results at point of care in a simple-to-operate, handheld instrument.
| PPA† | NPA* | Results in |
Compared to viral culture | 91.8% (95% CI: 85.9%, 95.4%) | 93.3% (95% CI: 90.4%, 94.4%) |
10 minutes
|
Compared to PCR | 81.6% (95% CI: 75.2%, 86.6%) | 99.1% (95% CI: 97.5%, 99.7%) | 10 minutes |
†positive percent agreement
‡negative percent agreement
Ordering information | Cat no. | Qty |
BD Veritor™ Plus System RSV CLIA-waived kit | 256038 | 30 tests |
BD Veritor™ Plus System RSV moderately complex kit | 256042 | 30 tests |
BD Veritor™ Plus Analyzer | 256066 | 1 unit |
†The BD Veritor™ RSV CLIA-waived kit is indicated for use in patients under 6 years of age. The BD Veritor™ RSV moderately complex kit is individual for use in patients under 20 years of age.
Adapts easily to your workflow by offering 2 operational modes
Option to test the same sample with a BD Veritor™ Flu A+B test device1
The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
1. BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV), package insert, 8086098. Franklin Lakes, NJ: Becton, Dickinson and Company BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
bd.com